Herpesvirus Antiviral Resistance
Database
Language
English
French
Spanish
German
CNR Website
Home
Login
Data
All data
Antivirals
Bibliography
Therapeutic targets
Tools
Search
Submit mutations
Request expertise
Genotyping tool
Contact
Notice
Last update : Wed 22 May 2024
TOP
Ganciclovir
Short name: GCV
Chembl ID:
CHEMBL182
SMILES (Simplified Molecular Input Line Entry System): C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Assays:
Filter:
Mutant
Gene
Type
Virus
EC50 ratio
Phenotype
Assay
Reference
Q229K
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
D247N
UL54
SNP
Human betaherpesvirus 5
0.90
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
D262N
UL54
SNP
Human betaherpesvirus 5
1.10
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
D271A
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
D288N
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
D301N
UL54
SNP
Human betaherpesvirus 5
2.60
Low level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E303G
UL54
SNP
Human betaherpesvirus 5
7.30
High level resistance
Details
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
E303D
UL54
SNP
Human betaherpesvirus 5
6.30
High level resistance
Details
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
F396L
UL54
SNP
Human betaherpesvirus 5
1.40
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
N408H
UL54
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
N408D
UL54
SNP
Human betaherpesvirus 5
4.90
Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
N408K
UL54
SNP
Human betaherpesvirus 5
4.20
Intermediate level resistance
Details
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
N408S
UL54
SNP
Human betaherpesvirus 5
3.10
Intermediate level resistance
Details
Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
N410K
UL54
SNP
Human betaherpesvirus 5
2.90
Low level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
F412C
UL54
SNP
Human betaherpesvirus 5
4.20
Intermediate level resistance
Details
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
F412L
UL54
SNP
Human betaherpesvirus 5
4.60
Intermediate level resistance
Details
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
F412S
UL54
SNP
Human betaherpesvirus 5
5.30
High level resistance
Details
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
F412V
UL54
SNP
Human betaherpesvirus 5
4.30
Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
D413A
UL54
SNP
Human betaherpesvirus 5
6.50
High level resistance
Details
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413E
UL54
SNP
Human betaherpesvirus 5
4.80
Intermediate level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
D413N
UL54
SNP
Human betaherpesvirus 5
3.80
Intermediate level resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
D413del
UL54
in/del
Human betaherpesvirus 5
3.80
Intermediate level resistance
Details
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
D413Y
UL54
SNP
Human betaherpesvirus 5
4.40
Intermediate level resistance
Details
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
L424V
UL54
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
F460L
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
V476G
UL54
SNP
Human betaherpesvirus 5
0.80
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
P488R
UL54
SNP
Human betaherpesvirus 5
3.50
Intermediate level resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
A492D
UL54
SNP
Human betaherpesvirus 5
1.35
No resistance
Details
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
N495K
UL54
SNP
Human betaherpesvirus 5
1.10
No resistance
Details
A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
K500N
UL54
SNP
Human betaherpesvirus 5
3.20
Intermediate level resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
L501F
UL54
SNP
Human betaherpesvirus 5
2.60
Low level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
L501I
UL54
SNP
Human betaherpesvirus 5
6.00
High level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
T503A
UL54
SNP
Human betaherpesvirus 5
3.10
Intermediate level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
T503I
UL54
SNP
Human betaherpesvirus 5
2.90
Low level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
A505V
UL54
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
K513Q
UL54
SNP
Human betaherpesvirus 5
6.60
High level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
K513E
UL54
SNP
Human betaherpesvirus 5
5.00
High level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
K513N
UL54
SNP
Human betaherpesvirus 5
6.00
High level resistance
Details
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
K513R
UL54
SNP
Human betaherpesvirus 5
3.70
Intermediate level resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
D515E
UL54
SNP
Human betaherpesvirus 5
2.70
Low level resistance
Details
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
D515Y
UL54
SNP
Human betaherpesvirus 5
6.20
High level resistance
Details
Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
L516R
UL54
SNP
Human betaherpesvirus 5
2.10
Low level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
L516W
UL54
SNP
Human betaherpesvirus 5
4.20
Intermediate level resistance
Details
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
I521T
UL54
SNP
Human betaherpesvirus 5
2.10
Low level resistance
Details
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522T
UL54
SNP
Human betaherpesvirus 5
2.10
Low level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
P522A
UL54
SNP
Human betaherpesvirus 5
3.00
Intermediate level resistance
Details
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522S
UL54
SNP
Human betaherpesvirus 5
3.10
Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
C524del
UL54
in/del
Human betaherpesvirus 5
3.50
Intermediate level resistance
Details
Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
V526L
UL54
SNP
Human betaherpesvirus 5
5.50
High level resistance
Details
Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
C539G
UL54
SNP
Human betaherpesvirus 5
3.10
Intermediate level resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
C539R
UL54
SNP
Human betaherpesvirus 5
3.20
Intermediate level resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
D542E
UL54
SNP
Human betaherpesvirus 5
1.50
No resistance
Details
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
A543S
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
L545F
UL54
SNP
Human betaherpesvirus 5
4.00
Intermediate level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
L545S
UL54
SNP
Human betaherpesvirus 5
3.50
Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
L545W
UL54
SNP
Human betaherpesvirus 5
4.90
Intermediate level resistance
Details
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
T552N
UL54
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
Q578H
UL54
SNP
Human betaherpesvirus 5
3.30
Intermediate level resistance
Details
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
Q578L
UL54
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
S585A
UL54
SNP
Human betaherpesvirus 5
1.50
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
D588E
UL54
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
D588N
UL54
SNP
Human betaherpesvirus 5
3.80
Intermediate level resistance
Details
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
C590F
UL54
SNP
Human betaherpesvirus 5
1.60
No resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
F595I
UL54
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
V654G
UL54
SNP
Human betaherpesvirus 5
1.10
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
S660G
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
G667N
UL54
SNP
Human betaherpesvirus 5
0.90
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
A692G
UL54
SNP
Human betaherpesvirus 5
0.80
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
T700A
UL54
SNP
Human betaherpesvirus 5
0.90
No resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
V715A
UL54
SNP
Human betaherpesvirus 5
1.77
No resistance
Details
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
V715M
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
I726T
UL54
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
I726V
UL54
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
E756D
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756K
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
E756Q
UL54
SNP
Human betaherpesvirus 5
1.70
No resistance
Details
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
L773V
UL54
SNP
Human betaherpesvirus 5
3.00
Intermediate level resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
L776M
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
V781I
UL54
SNP
Human betaherpesvirus 5
1.00-4.00
Range of values between No resistance and Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
V787A
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
V787E
UL54
SNP
Human betaherpesvirus 5
8.60
High level resistance
Details
Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
V787L
UL54
SNP
Human betaherpesvirus 5
2.40
Low level resistance
Details
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
E793V
UL54
SNP
Human betaherpesvirus 5
0.90
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
Q795P
UL54
SNP
Human betaherpesvirus 5
0.90
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
Q795R
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
L802M
UL54
SNP
Human betaherpesvirus 5
1.10-3.50
Range of values between No resistance and Intermediate level resistance
Details
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
L802V
UL54
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
K805Q
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
A809V
UL54
SNP
Human betaherpesvirus 5
2.60
Low level resistance
Details
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
V812L
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
T813S
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
T821I
UL54
SNP
Human betaherpesvirus 5
4.50
Intermediate level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
M827I
UL54
SNP
Human betaherpesvirus 5
Natural polymorphism
Details
Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
P829S
UL54
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
A834P
UL54
SNP
Human betaherpesvirus 5
5.40
High level resistance
Details
Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
T838A
UL54
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
G841S
UL54
SNP
Human betaherpesvirus 5
2.20
Low level resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
G841A
UL54
SNP
Human betaherpesvirus 5
3.20
Intermediate level resistance
Details
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
M844T
UL54
SNP
Human betaherpesvirus 5
1.40
No resistance
Details
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844V
UL54
SNP
Human betaherpesvirus 5
2.50
Low level resistance
Details
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
P859A
UL54
SNP
Human betaherpesvirus 5
0.80
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
L862F
UL54
SNP
Human betaherpesvirus 5
1.70
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
V902G
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
V946L
UL54
SNP
Human betaherpesvirus 5
1.10
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
K947E
UL54
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
L957F
UL54
SNP
Human betaherpesvirus 5
2.70
Low level resistance
Details
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
M959T
UL54
SNP
Human betaherpesvirus 5
1.20
No resistance
Details
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
981-982del
UL54
in/del
Human betaherpesvirus 5
6.70
High level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
D981del
UL54
in/del
Human betaherpesvirus 5
8.30
High level resistance
Details
A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
A987G
UL54
SNP
Human betaherpesvirus 5
5.30
High level resistance
Details
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
L337M
UL97
SNP
Human betaherpesvirus 5
1.02
No resistance
Details
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
F342S
UL97
SNP
Human betaherpesvirus 5
7.80
High level resistance
Details
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
F342Y
UL97
SNP
Human betaherpesvirus 5
6.00
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
V353A
UL97
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
K355del
UL97
in/del
Human betaherpesvirus 5
16.00
High level resistance
Details
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
V356G
UL97
SNP
Human betaherpesvirus 5
5.50
High level resistance
Details
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
K359E
UL97
SNP
Human betaherpesvirus 5
4.00
Intermediate level resistance
Details
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
K359Q
UL97
SNP
Human betaherpesvirus 5
4.00
Intermediate level resistance
Details
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
L397R
UL97
SNP
Human betaherpesvirus 5
2.30
Low level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L405P
UL97
SNP
Human betaherpesvirus 5
2.70
Low level resistance
Details
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
T409M
UL97
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H411L
UL97
SNP
Human betaherpesvirus 5
0.70
No resistance
Details
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411N
UL97
SNP
Human betaherpesvirus 5
0.71
No resistance
Details
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411Y
UL97
SNP
Human betaherpesvirus 5
0.50
No resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A427V
UL97
SNP
Human betaherpesvirus 5
0.95
No resistance
Details
Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
D456N
UL97
SNP
Human betaherpesvirus 5
12.00
High level resistance
Details
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
M460I
UL97
SNP
Human betaherpesvirus 5
12.00
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460T
UL97
SNP
Human betaherpesvirus 5
9.30
High level resistance
Details
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
M460V
UL97
SNP
Human betaherpesvirus 5
9.10
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
V466G
UL97
SNP
Human betaherpesvirus 5
11.00
High level resistance
Details
Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
V466M
UL97
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
H469Y
UL97
SNP
Human betaherpesvirus 5
1.00
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
R476C
UL97
SNP
Human betaherpesvirus 5
Details
Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
A478V
UL97
SNP
Human betaherpesvirus 5
0.85
No resistance
Details
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
C480F
UL97
SNP
Human betaherpesvirus 5
2.30
Low level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C480R
UL97
SNP
Human betaherpesvirus 5
9.00
High level resistance
Details
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
C518Y
UL97
SNP
Human betaherpesvirus 5
12.00
High level resistance
Details
Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
H520Q
UL97
SNP
Human betaherpesvirus 5
9.70
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
P521L
UL97
SNP
Human betaherpesvirus 5
17.00
High level resistance
Details
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
590-600del
UL97
in/del
Human betaherpesvirus 5
6.30
High level resistance
Details
Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001)
590-603del
UL97
in/del
Human betaherpesvirus 5
Details
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. (Aug 1999)
591-594del
UL97
in/del
Human betaherpesvirus 5
6.00
High level resistance
Details
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. (Sep 1992)
A591V
UL97
SNP
Human betaherpesvirus 5
1.30
No resistance
Details
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
591-607del
UL97
in/del
Human betaherpesvirus 5
6.20
High level resistance
Details
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
C592F
UL97
SNP
Human betaherpesvirus 5
31.50
High level resistance
Details
Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. (Sep 2001)
C592G
UL97
SNP
Human betaherpesvirus 5
3.20
Intermediate level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594E
UL97
SNP
Human betaherpesvirus 5
3.00
Intermediate level resistance
Details
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
A594G
UL97
SNP
Human betaherpesvirus 5
13.50
High level resistance
Details
Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. (Sep 1997)
A594P
UL97
SNP
Human betaherpesvirus 5
7.90
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594S
UL97
SNP
Human betaherpesvirus 5
2.20-4.90
Range of values between Low level resistance and Intermediate level resistance
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
A594T
UL97
SNP
Human betaherpesvirus 5
5.00
High level resistance
Details
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
A594V
UL97
SNP
Human betaherpesvirus 5
6.90
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595F
UL97
SNP
Human betaherpesvirus 5
6.20
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595S
UL97
SNP
Human betaherpesvirus 5
7.50
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595W
UL97
SNP
Human betaherpesvirus 5
9.00
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595del
UL97
in/del
Human betaherpesvirus 5
13.30
High level resistance
Details
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. (Feb 1995)
595-603del
UL97
in/del
Human betaherpesvirus 5
8.40
High level resistance
Details
Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. (Mar 1999)
E596Q
UL97
SNP
Human betaherpesvirus 5
2.70
Low level resistance
Details
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
E596del
UL97
in/del
Human betaherpesvirus 5
Details
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
E596G
UL97
SNP
Human betaherpesvirus 5
2.30
Low level resistance
Details
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
E596Y
UL97
SNP
Human betaherpesvirus 5
6.40
High level resistance
Details
Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
N597del
UL97
in/del
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
597-598del
UL97
in/del
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
597-599del
UL97
in/del
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
G598S
UL97
SNP
Human betaherpesvirus 5
Details
Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. (May 1998)
599-603del
UL97
in/del
Human betaherpesvirus 5
5.30
High level resistance
Details
Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
K599E
UL97
SNP
Human betaherpesvirus 5
Details
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
K599R
UL97
SNP
Human betaherpesvirus 5
1.10
No resistance
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
K599T
UL97
SNP
Human betaherpesvirus 5
5.30
High level resistance
Details
Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
L600I
UL97
SNP
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
L600del
UL97
in/del
Human betaherpesvirus 5
1.90
No resistance
Details
Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. (Nov 2001)
T601M
UL97
SNP
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
601-602del
UL97
in/del
Human betaherpesvirus 5
11.00
High level resistance
Details
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
601-603del
UL97
in/del
Human betaherpesvirus 5
11.00
High level resistance
Details
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
C603R
UL97
SNP
Human betaherpesvirus 5
Details
Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
C603S
UL97
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
C603W
UL97
SNP
Human betaherpesvirus 5
5.90
High level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603Y
UL97
SNP
Human betaherpesvirus 5
2.80
Low level resistance
Details
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
D605E
UL97
SNP
Human betaherpesvirus 5
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
C607F
UL97
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
C607Y
UL97
SNP
Human betaherpesvirus 5
12.50
High level resistance
Details
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
I610T
UL97
SNP
Human betaherpesvirus 5
2.60
Low level resistance
Details
Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
A613V
UL97
SNP
Human betaherpesvirus 5
2.30
Low level resistance
Details
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013)
Y617del
UL97
in/del
Human betaherpesvirus 5
10.00
High level resistance
Details
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
E655K
UL97
SNP
Human betaherpesvirus 5
1.70
No resistance
Details
Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)